Welcome to our dedicated page for Nls Pharmaceutics news (Ticker: NLSP), a resource for investors and traders seeking the latest updates and insights on Nls Pharmaceutics stock.
NLS Pharmaceutics Ltd (NLSP) delivers cutting-edge therapies for central nervous system disorders through innovative platforms like its dual orexin receptor agonist (DOXA) technology. This page provides essential updates for stakeholders tracking clinical developments, strategic partnerships, and regulatory milestones in neuropharmaceutical research.
Access verified press releases and analysis on NLSP's progress in addressing narcolepsy, neurodegenerative diseases, and cognitive disorders. Our curated news collection covers clinical trial results, intellectual property developments, and financial performance updates critical for informed decision-making.
Key content includes updates on the Kadimastem merger's therapeutic pipeline expansion, DOXA platform validation studies, and collaborative research initiatives. Investors will find timely reports on funding rounds, patent approvals, and preclinical data disclosures.
Bookmark this page for consolidated access to NLSP's latest advancements in CNS therapy development. Regularly updated to reflect material events and scientific breakthroughs, it serves as your primary resource for understanding the company's position in competitive biopharmaceutical markets.
NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) announced that CEO Alex Zwyer will present at the Canaccord Genuity 41st Annual Growth Conference from August 10-12, 2021. Zwyer's presentation is scheduled for August 12, 2021, at 10:00 AM ET and will be available for live streaming and replay on the company's website. NLS focuses on innovative therapies for rare central nervous system disorders, with its lead product, Quilience, developed for narcolepsy treatment and holding orphan drug designations in the U.S. and Europe.
NLS Pharmaceutics Ltd. has appointed Eric Konofal, M.D., Ph.D., as Chief Scientific Officer. Dr. Konofal, a co-founder with over 30 years of experience in CNS disorders, will focus on advancing the company’s drug pipeline, which includes Quilience® for narcolepsy and five other patented compounds. His leadership is expected to enhance drug development efforts, particularly against disorders like ADHD and Parkinson’s disease. The company recently submitted multiple patent applications, which could strengthen its market position.
NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) announced that the FDA has accepted its Investigational New Drug application for Quilience (mazindol ER), the lead candidate for treating narcolepsy. The company plans to launch a Phase 2a clinical trial in August 2021 across the U.S. and Europe, enrolling about 60 patients. The primary objective is to assess changes in excessive daytime sleepiness using the Epworth Sleepiness Scale, with secondary endpoints related to cataplexy attacks. This milestone emphasizes NLS's commitment to developing treatments for central nervous system disorders.
STANS, SWITZERLAND / ACCESSWIRE / July 9, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) announced that CEO Alex Zwyer will present a corporate overview at the First Annual Access to Giving Virtual Investor Conference from July 13-15, 2021. The presentation is scheduled for July 15th at 9:00 am ET, followed by a Q&A session. NLS focuses on innovative therapies for rare central nervous system disorders, with its lead candidate, Quilience®, aimed at treating narcolepsy, receiving Orphan Drug Designations in the U.S. and Europe.
NLS Pharmaceutics Ltd. (NASDAQ: NLSP) will present a corporate overview at the LD Micro Virtual Invitational Conference from June 8-10, 2021. CEO Alex Zwyer is set to deliver the presentation on June 10 at 11:30 AM ET on Track 2. The company's lead product, Quilience®, a controlled-release formulation of mazindol, is designed to treat narcolepsy and has received Orphan Drug Designations in both the U.S. and Europe. NLS completed a successful Phase 2 study on mazindol CR for ADHD, meeting all study endpoints.
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) is set to present a corporate overview at the MicroCap Rodeo 2021 Summer Solstice Conference from June 1-4, 2021. CEO Alex Zwyer will deliver the presentation on June 2 at 8:30 AM ET and will engage in one-on-one meetings throughout the event. The presentation will be webcast live, with a replay available for later viewing. NLS is focused on developing therapies for rare central nervous system disorders, with its lead product candidate, Quilience®, targeting narcolepsy. For more details and to register, visit the company’s website.
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) announced new study data confirming mazindol's mechanism of action as an Orexin-2 receptor (OX2R) agonist, essential for treating narcolepsy. In a pre-clinical study, genetically modified mice demonstrated significantly reduced sensitivity to mazindol, reinforcing its potent neurochemical activity. Ongoing studies aim to expand on these findings, emphasizing mazindol's potential dual mechanism of action in addressing narcolepsy's core symptoms. The company remains committed to developing Quilience®, a controlled-release formulation of mazindol, with hopes of improving treatment efficacy.
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) has appointed Dr. Silvia Panigone as Chief Operating Officer, effective immediately. Dr. Panigone brings over 25 years of experience in healthcare, having previously led ADYA Consulting and served in various roles within international pharmaceutical companies. Her expertise will be pivotal as NLS advances its lead drug, Quilience®, designed for treating narcolepsy. The company aims to secure IND approval in the U.S. and move Quilience into clinical stages, addressing significant unmet medical needs in CNS disorders.
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) announced the issuance of Canadian Patent No. 3016852 for its controlled-release mazindol formulation aimed at treating ADHD and related disorders. This patent provides intellectual property protection for a multilayer tablet combining immediate and sustained-release properties. CEO Alex Zwyer emphasized the potential of Quilience® to address unmet needs in narcolepsy treatment. NLS's European patent application is also progressing, with a Phase 2 clinical study for Quilience planned. The company holds Orphan Drug Designations for this drug in the U.S. and Europe.
NLS Pharmaceutics Ltd. (NLSP) has entered a License Agreement with Novartis Pharma AG, securing exclusive rights in the U.S. for all data related to the NDA for Sanorex® (mazindol). This agreement also extends non-exclusively outside the U.S., excluding Japan. The CEO stated this acquisition may streamline clinical processes and reduce costs, enhancing the development of Quilience®, a controlled release formulation of mazindol aimed at treating narcolepsy and related sleep disorders. Quilience has received Orphan Drug Designation in the U.S. and Europe.
